Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity
Executive Summary
Schwarz Pharma is exploring a scenario where it would win a favorable decision in the Prilosec patent case, while generic omeprazole marketing exclusivity holder Andrx loses on non-infringement
You may also be interested in...
Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz
Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not
Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz
Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not
Prilosec OTC Switch Set For Early 2003 Following FDA “Approvable” Letter
AstraZeneca's OTC switch for Prilosec (omeprazole) will wait until 2003 after receipt of an "approvable" letter from FDA